PTC finds it­self in quag­mire of reg­u­la­to­ry set­backs, push­es back time­line on PKU treat­ment

PTC Ther­a­peu­tics has de­layed its plans by nine months to ap­ply for FDA ap­proval of its treat­ment for phenylke­tonuria, a rare dis­ease that caus­es pro­tein build­ing blocks to ac­cu­mu­late in the body, af­ter the agency asked for a new mouse study.

Orig­i­nal­ly, PTC want­ed to sub­mit its FDA fil­ing for sepi­apterin be­fore the end of this year. Now, the agency asked for a half-year mouse study on the drug’s can­cer risk. PTC ex­pects it will sub­mit for po­ten­tial FDA ap­proval in the third quar­ter of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER